Dott. Gianluca Aloe

Specialista in Oftalmologia, a novembre 2018 ho vinto il dottorato di ricerca in "Scienze Medico-Chirurgiche Applicate" presso l'Università Tor Vergata di Roma. Mi occupo principalmente di patologie della retina e di degenerazione maculare legata all'età. Eseguo interventi sul segmento anteriore ed in particolare la chirurgia della cataratta. Ad agosto 2018 ho partecipato ad un “Phacoemulsification Training Course” tenutosi presso il “Eye Research Centre & Dr. Agarwal’s Eye Hospital” a Chennai, in India, per perfezionare le mie abilità nella chirurgia del segmento anteriore. Eseguo trattamenti laser retinici e terapie intravitreali per degenerazione maculare senile. Il mio interesse principale attualmente è rivolto verso l'applicazione della medicina genomica nello studio della malattie retiniche, in particolare della degenerazione maculare senile.

• Cataratta

---

• Retinopatia

---

• Glaucoma

---

• Degenerazione maculare

---

• Astigmatismo

---

• Ipermetropia

---

• Miopia

---

• Calazio

---

• Distacco della retina

---

• Ipovisione

---

• Occhio secco

---

• Neurite ottica

---

• Retinopatia diabetica

---

• Trombosi venosa

• Internato Elettivo di “Anatomia Patologica” svolto nell’a.a. 2008/2009 presso Università “Sapienza” –Roma

  ---

• Internato Elettivo presso Ambulatorio di Maculopatie svolto negli a.a. 2009/2010 e 2010/2011 presso Università “Sapienza” –Roma.

  ---

• 2015- Sub Investigator OLIMPIC; A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia

  ---

• 2015- Sub Investigator CHROMA: a phase III, multicenter, randomized, double-masked, sham-controlled study of efficacy and safety of 10 mg lampalizumab intravitreal injections administered every 30 or 45 days to patients with geographic atrophy secondary to age-related macular degeneration.

  ---

• 2015- Sub Investigator TWEYES: a 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With BCVA Below 2/10 and/or Second Affected Eye

  ---

• 2016- Sub Investigator OBTAIN: A 36 month observational study to describe the long-term efficacy and safety of ranibizumab 0.5 mg treatment in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM)

  ---

• 2016- Sub Investigator HARRIER RTH258: A Two-Year,Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH2586 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration

  ---

• 2016- Sub Investigator AQUA. Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment

  ---

• “Phacoemulsification Training Course” tenutosi presso il “Eye Research Centre & Dr. Agarwal’s Eye Hospital”, Chennai, India 2018.